VNDA Rentabilitas dodolan reged Vanda Pharma

Lambang korporat lan logo Vanda Pharmaceuticals Inc (VNDA)

Vanda Pharmaceuticals specializes in developing medications to combat psychiatric disorders and sleep disturbances. The target gross margin confirms the resilience of these operations, with 89.30 recorded as the baseline value. Portfolio diversification mitigates patent risks, although profits rely on the sales of key drugs, necessitating strict control over litigation and generics.

VNDA - Margin reged Vanda Pharmaceuticals ing rentang 04.07.2022 - 20.11.2026

Rincian analitis lan laporan data perusahaan Vanda Pharmaceuticals Inc (VNDA)

- nilai pasar lan prakiraan target analis:
Produk sing diprodhuksi Vanda Pharma

For Vanda Pharmaceuticals (VNDA), which is developing Hetlioz and Fanapt for CNS therapy, the gross profit margin reflects the efficiency of managing direct production costs. This metric is calculated as the ratio of the difference between revenue and cost of goods sold to total sales, allowing investors to assess the resilience of business margins against rising production expenses and the risk of contracting operating returns.